$MOBI

Curnes Nelson Bunker purchased $64K of MOBI

Curnes Nelson Bunker (Chief Financial Officer) purchased 5,000 shares of Mobia Medical, Inc. (MOBI) at $12.79 on 2026-06-09.

Original reporting
SEC EDGAR · Curnes Nelson Bunker
Published Jun 11, 2026, 11:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 11:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MOBI
Bullish
medium confidence
Mentioned
$MOBI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBIBullishLow
01

Why it matters

The newest fact is the CFO’s open-market purchase (5,000 shares at $12.7938) and the resulting post-transaction holdings (366,997 shares).

02

Market read

Provides a modest insider-buy datapoint that may slightly influence sentiment, but lacks fundamental catalysts.

03

What to watch

The filing does not state intent, timing constraints, or whether the purchase follows prior sales; traders should check for recent insider sale activity and broader liquidity/float dynamics.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-11; purchase dated 2026-06-09

Background

The article is an SEC Form 4 insider transaction disclosure for Mobia Medical, Inc.

Company-level read

Ticker impact

$MOBIBullishMedium confidence
Context

CFO Curnes Nelson Bunker filed an open-market purchase of 5,000 shares of Mobia Medical (MOBI) on 2026-06-09 for ~$63,969.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 is a primary-source insider transaction, but the dollar size is relatively small and there is no accompanying guidance, deal, or regulatory action in the text.

Market effects

No sector read-across provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or pre-planned behavior; without a 10b5-1 plan or larger size, signal strength is limited.

Key entities

  • Mobia Medical, Inc.

    Subject of the Form 4 insider transaction disclosure (MOBI).

  • Curnes Nelson Bunker

    Chief Financial Officer who purchased 5,000 shares on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

$MOBIMedAI 8/10

Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.

$MOBIMed

Mobia Medical, Inc. (MOBI): Results of Operations and Financial Condition

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial re

$MOBIMedAI 8/10

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.